Join
Live feed
·
PRReleasevia Quantisnow
Acrivon Therapeutics Inc. logo

UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

ByQuantisnow·Wall Street's wire, on your screen.
ACRV· Acrivon Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ACRV (Acrivon Therapeutics Inc.) and more on Quantisnow.